Review
PTK/ZK (Novartis)
Affiliations
- PMID: 12917775
Item in Clipboard
Review
PTK/ZK (Novartis)
IDrugs.
2003 Aug.
Abstract
PTK/ZK, a VEGF receptor tyrosine kinase inhibitor, is under development by Novartis AG and Schering AG as an inhibitor of angiogenesis for the potential treatment of various cancers.
Similar articles
-
Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastases.Cancer Chemother Pharmacol. 2006 Jun;57(6):761-71. doi: 10.1007/s00280-005-0120-6. Epub 2005 Sep 20. Cancer Chemother Pharmacol. 2006. PMID: 16172907 Clinical Trial.
-
PTK 787/ZK 222584, a tyrosine kinase inhibitor of all known VEGF receptors, represses tumor growth with high efficacy.Chembiochem. 2005 Mar;6(3):550-7. doi: 10.1002/cbic.200400305. Chembiochem. 2005. PMID: 15742376
-
Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours.Eur J Cancer. 2005 Jun;41(9):1291-9. doi: 10.1016/j.ejca.2005.03.005. Eur J Cancer. 2005. PMID: 15939265 Clinical Trial.
-
Vascular endothelial growth factor receptor tyrosine kinase inhibitors: PTK787/ZK 222584.Semin Oncol. 2003 Jun;30(3 Suppl 6):32-8. doi: 10.1016/s0093-7754(03)00123-4. Semin Oncol. 2003. PMID: 12802793 Review.
-
Current studies with PTK787, an oral inhibitor of vascular endothelial growth factor in colorectal cancer.Clin Colorectal Cancer. 2003 Nov;3(3):147-9. doi: 10.1016/S1533-0028(11)70081-0. Clin Colorectal Cancer. 2003. PMID: 14706172 Review. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources